Search

Displaying results 1781 - 1790 of 10000 in total
  1. Drug

    Vapitadine

    go.drugbank.com/drugs/DB05738
    Experimental

    Vapitadine is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis

  2. Drug

    RPI-78M

    go.drugbank.com/drugs/DB05740
    Experimental

    RPI-78M is being developed for the treatment of multiple sclerosis (MS).

  3. Drug

    CRx-139

    go.drugbank.com/drugs/DB05744
    Experimental

    It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects. … This novel synergistic combination is developed for the treatment of immuno-inflammatory diseases.

  4. Drug

    RP01

    go.drugbank.com/drugs/DB05751
    Experimental

    RP01 is a novel anti-IgE immunotherapy for allergic individuals. … It is designed to induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of an allergic response.

  5. Drug

    CYT007-TNFQb

    go.drugbank.com/drugs/DB05758
    Experimental

    CYT007-TNFQb is an active immunization therapy that aims at providing a novel treatment to people suffering from RA or psoriasis.

  6. Drug

    ATX-201

    go.drugbank.com/drugs/DB05765
    Investigational

    ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis.

  7. Drug

    Andrographolide

    go.drugbank.com/drugs/DB05767
    Investigational

    Andrographolide (HMPL-004) is a botanical product extracted from a herb that occurs naturally in China.

    Synonyms: 3α,14,15,18-tetrahydroxy-5b,9bH,10a-labda-8(20),12-dien-16-oic acid γ-Lactone
  8. Drug

    Rabeximod

    go.drugbank.com/drugs/DB05772
    Investigational

    Rabeximod is an orally administered compound for treatment of moderate or severe active rheumatoid arthritis that is currently undergoing phase II clinical testing in eight European countries.

    Categories: Heterocyclic Compounds, 2-Ring
  9. Drug

    Trastuzumab emtansine

    go.drugbank.com/drugs/DB05773
    ApprovedInvestigational

    Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity. … Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: T-DM1
  10. Drug

    CRx-401

    go.drugbank.com/drugs/DB05775
    Experimental

    CRx-401 is a novel insulin sensitizer designed to provide anti-diabetic activity without promoting weight gain. … It consists of a low dose of the analgesic diflunisal in conjunction with a modified-release therapeutic dose of bezafibrate, an anti-cholesterol agent.